Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;9(6):785-93.
doi: 10.1586/era.09.43.

Targeting the Met signaling pathway in renal cancer

Alessio Giubellino  1 , W Marston Linehan, Donald P Bottaro
Affiliations
Review

Targeting the Met signaling pathway in renal cancer

Alessio Giubellino et al. Expert Rev Anticancer Ther. 2009 Jun.

Abstract

Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for 3% of all adult malignancies and its incidence has significantly increased over the last 20 years. RCC claims 13,000 lives annually in the USA and more than 100,000 worldwide. A better understanding of the molecular basis of RCC has facilitated the development of novel and more selective therapeutic approaches. An important role in RCC oncogenesis is played by the receptor for HGF, Met, which has attracted considerable attention, more recently as a molecular target for cancer therapy, and several drugs selectively targeting this pathway are now in clinical trials. This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008;58(2):71–96. - PubMed
    1. Linehan WM. Kidney cancer: opportunity for disease specific targeted therapy. Urol. Oncol. 2008;26(5):542. - PMC - PubMed
    1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Datab. Syst. Rev. 2005;1:CD001425. - PubMed
    1. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 2007;13(2 II) - PubMed
    1. Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–2067. - PubMed

    2. Excellent review on von Hippel-Lindau disease.

Publication types

MeSH terms

Substances